

CURRICULUM VITAE



A. Personal Information:

Name Jorge J. Nieva
Business Address Department of Clinical Medicine
USC Norris Comprehensive Cancer Center
1441 Eastlake Ave., Suite 3440
Los Angeles, CA 90033-9173
Business Phone (323) 865-0421
Business Fax (323) 865-0061
E-mail Address jorge.nieva@med.usc.edu
Home Address 1218 Solita Road
Pasadena, CA 91103
Home Phone (406) 371-5797
Citizenship USA
E-mail Address jnievamt@gmail.com

B. Education:

University University of California, Irvine, Irvine, CA, Medicine, M.D.,
1993-1997
University of California, Irvine, Irvine, CA, Biological
Sciences, B.S., 1989-1992
Postgraduate Training Fellow, Division of Hematology and Oncology, Scripps Clinic,
La Jolla, CA, 2000-2003
Resident, Internal Medicine, University of California, San
Diego, San Diego, CA, 1998-2000
Internship, Internal Medicine, University of California, San
Diego, San Diego, CA, 1997-1998
Honors Excellence in Research, University of California, Irvine, 1992
American Association of Pathology Chairs Honor Society, 1995
Irving M. Reingold Prize in Pathology, 1995
Walter Blumenson Scholarship for Academic Promise, 1997
Department of Medicine Award, University of California,
Irvine, 1997
Alpha Omega Alpha Medical Honors Society, 1997
Waltz Award for Leadership, Scripps Clinic, La Jolla, 2003
Skaggs Scholar in Clinical Science, 2003
Outstanding Teacher Award, Scripps Clinic, La Jolla, 2004
National Cancer Institute Gold Certificate of Excellence, 2011
ASCO Award for Excellence in Clinical Trials, 2012
USC Medical Oncology Faculty Award for Excellence in
Teaching, 2015, 2018

C. Professional Background:

Academic Appointments

Hematologist/Oncologist, The Scripps Clinic, La Jolla, CA, 2003-2007
Assistant Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, 2003-2007
Hematologist/Oncologist, The Billings Clinic, Billings, MT, 2007-2014
Adjunct Professor of Cell Biology, The Scripps Research Institute, La Jolla, CA, 2012-2015
Associate Professor of Clinical Medicine, University of Southern California, Los Angeles, CA, 2014-present

Administrative Appointments

Assistant Director, Translational Research, Scripps Cancer Center, La Jolla, CA, 2003-2004
Director, Andrew J. and Erna F. Viterbi, Department of Translational Research Scripps Cancer Center, La Jolla CA, 2004-2007
Department Chairman, Hematology/Oncology, Billings Clinic, Billings, MT, 2010-2014
Section Head, Solid Tumors, USC/Norris Cancer Center 2018-
Oncology Drug Advisory Committee, United States Food and Drug Administration 2021-

Teaching

University of Southern California

Lecturer, Postgraduate IM Resident Medical Oncology Lectures, 4 Units, Lung & Head/Neck Cancer, 2014-
Lecturer, Fellow's Lecture Series, 4 Units, Lung & Head/Neck Cancer, 2014-
Lecturer, Introduction to Clinical Medicine, 12 Units, Cancer Screening, 2014-

Rocky Mountain College

Lecturer, Hematology Oncology, 2 Units, Leukemia, 2008-2010

CME Courses Developed – Western Student and Resident Medical Research Forum

Executive Co-Director, Western Regional Meetings, 16 Units, 2014-

Training Record

Medical Residents

Sonia Lin, 2014-2016, Disparities in Care of NSCLC
Gino In, 2014-2016, Patterns of Metastasis in NSCLC
Alexander Martin, 2017-2018, Objective Metrics of Patient Performance in Cancer
Arnab Basu 2018-2019, KRAS in lung cancer
Jonathan Chang 2018-2019, Research Biopsies in Cancer Clinical Trials
Elizabeth Pan 2018-2019, Validity of Cancer Models in Lung Cancer
Christina Vu 2018-2019, CT Screening of Asian Populations for NSCLC
Amanda Herrmann 2018-2019, Genomics of Resistance in EGFR/ALK NSCLC
Christopher Wang 2020-2022, Objective Measures of Performance Status
Karen Resnick 2020-2022, Liquid Biopsy Screening for Lung Cancer

Graduate Students

Dena Marrinucci, 2004-2008, Circulating Tumor Cells in Cancer
Jeremy Mason, 2012-2016, Markov Modeling of Cancer
Paymaneh Malihi, 2015-2019, Predicting outcomes in Prostate Cancer
Zaki Hasnain, 2014-2018, Movement Trackers in Evaluation of Cancer Patients
Lisa Welter, 2016-2019, Evolution in Breast Cancer
Xiayu Jiao, 2017-2019, Pharmaco-economics in lung cancer
Joseph Larson 2018-2019, Progression of Breast Cancer in Pseudotime
Tanachat Nilanon 2018-2019, Wearable Trackers in Cancer Patients
Rishvanth Prabacker 2019, Short Read Sequencing on Long Read Sequencers
Ryan Cooper, 2020-2022, Bias in Clinical Trial Enrollment Criteria

D. Society Memberships:

National

American Society of Clinical Oncology, 2003-present
American Society of Hematology, 2004-2012
American Association for Cancer Research, 2005-2007, 2015-present

E. Service:

Department

Thoracic Oncology Program Development, Hoag Cancer Center, 2015
Medical Oncology Graduate Medical Education Evaluations Committee, GME, 2015-2016

Medical School

Resident Research Advisor, Scripps Clinic Graduate Medical Education, LA Jolla, CA, 2003-2007

Clinical Competency Committee, USC Medical Oncology, 2015-2018

Hospital or Medical Group

Cancer Conference Committee Chair, Billings Clinic, Billings, MT, 2007-2014
Program Leader, Thoracic Oncology, Billings Clinic, Billings, MT, 2007-2014
Program Leader, Head and Neck Oncology, Billings Clinic, Billings, MT, 2009-2014
Member, Cancer Committee, Norris Cancer Center, Los Angeles, CA, 2016
Oncology Strategic Planning Steering Committee, Norris Cancer Hospital, Los Angeles, CA, 2016
Thoracic Oncology Program Co-Leader

University

Disease-Site Head, Thoracic and Head & Neck Malignancies, Translational and Clinical Sciences Program, USC/Norris Cancer Center, 2018-
Reviewer, Clinical Investigations Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2014-present
Leadership Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2016-2017
Chairman, Data and Safety Monitoring Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2017-present
Task Force Member for Equity and Diversity, Keck School of Medicine, Department of Medicine 2019
Internal Advisory Board, USC-FAMU-UF Cancer Health Equity Center 2019-Present

Professional

Project Team Member, Ixazomib & Pevonedistat, Clinical Trials Network, CTEP, NCI 2017
Project Team Member, CO-1686 Team, Clinical Trials Network, CTEP, NCI, 2015
Contributor, Advanced Lung Cancer, Remedy Health Guide, 2017

Advisory Boards

Speaker's Bureau, Sanofi-Aventis Inc., 2005
Clinical Advisory Board, Anaborex Inc., 2005-2007
Speaker's Bureau, Cytogen Inc., 2006
Speaker's Bureau, Amgen, 2008-2011
Speaker's Bureau, Lilly, 2009-2011
Speaker's Bureau, Boehringer-Ingelheim, 2013-2014
Scientific Advisory Board, Indee Inc. 2016
Clinical Advisory Board, Western Oncolytics, 2018
Scientific Advisory Board, Kyoku Inc 2019
Scientific Advisory Board, Quantgene Inc. 2019

Editorial Boards

Editor, *Convergent Science Physical Oncology*, IOP Publishing, 2014-2017
Associate Editor, *Frontiers in Oncology*, 2019-2021

Journal Reviews

Convergent Science Physical Oncology, 2014-2017
Nature: Scientific Reports, 2016
Journal of the National Cancer Institute, 2016
BMC Cancer, 2018
Clinical and Translational Medicine 2020
ASCO's Clinical Cancer Informatics 2020-2021
Future Oncology 2021
Biomarkers in Medicine 2021
Translational Lung Cancer Research 2021

Grant Reviews

Reviewer, Proteomic Technology Assessment Resources, National Cancer Institute, 2006
Reviewer, Early Detection Research Network, National Cancer Institute, 2010
Reviewer, National Centers for Biomedical Computing, 2010
Reviewer NCI IMAT Innovative and Applied Emerging Technologies in Biospecimen Science, National Cancer Institute, 2012-2014
Reviewer, VA ONCO B Merit Awards, National Cancer Institute, 2014-2015
Reviewer, Exploratory and Developmental Studies, National Cancer Institute 2017
Reviewer, Extramural Loan Repayment Program, National Center for Advancing Translation Sciences, 2017
Reviewer, NCI Omnibus Exploratory Grants Program R21/R03 2018-20
Reviewer, NIH Loan Repayment Program L30/L40 2019-20

Consultantships

Consultant, Genoptix, Inc., 2005-2006
Consultant, Genomics Institute of the Novartis Research Foundation, 2005-2007
Consultant, Alexion Antibody Technologies, 2005-2007
Consultant, ZLB Behring, 2006
Consultant, Genentech, 2015
Consultant, Turnstone Biologics, 2016
Consultant, Jooster, Inc., 2016-2017
Consultant, Astra Zeneca, 2017, 2019
Consultant, Genentech 2017
Consultant, Takeda 2018
Consultant, Fujirebio 2019

Community

- Webinar Speaker, Cancer Information and Support Network, Patient Advocates Education, 2015
- Conference Speaker, Community Health Conference, Indian Wells Country Club, Indian Wells, CA, 2015
- Conference Speaker, Hack for Health, University of Southern California, Los Angeles, CA 2017
- Event Chair, Your Next Step is the Cure, Addario Lung Cancer Foundation, San Dimas, CA 2018
- Radio Guest, Cancer Screening, Exitos 99.9, Caracas, Venezuela, 2019
- Invited Speaker, Bravo Magnet High School virtual lecture – Careers in Medicine Los Angeles 2021
- Invited Speaker, Epidemiology of Young Lung Cancer Go2 Foundation Center of Excellence Summit. 2021

Invited Lectures, Symposia, Keynote Addresses

- Keynote Speaker, Cancer Survivor's Day, Scripps Clinic, La Jolla, CA, 2006
- Symposium Speaker, Circulating Tumor Cells, Big Sky ONS, Billings, MT, 2007
- Symposium Speaker, Telemedicine in Oncology, EMTN Retreat, Billings, MT, 2008
- Symposium Speaker, New Oncology Drugs in Development, Big Sky ONS, Billings, MT, 2010
- Symposium Speaker, Clinical Relevance of the Fluid Biopsy, PSOC Annual Meeting, Washington, DC, 2011
- Conference Speaker, HD-CTC Assay: Real Time Fluid Biopsy of Solid Tumors, USC, Los Angeles, CA, 2011
- Symposium Speaker, Clinical Applications of Newton's Model of Metastasis, PSOC Annual Meeting, Washington, DC, 2013
- Symposium Speaker, Getting Access to Data- Lots of Data, BD2K Symposium, Washington, DC, 2014
- Symposium Speaker, Building the Oncology System of the Future, Cancer Center Business Summit, Washington, DC, 2014
- Symposium Speaker, Precision Objective Measures for Cancer, Remote Medicine, and Discovery, Washington, DC, 2017
- Conference Speaker, USC's IMSC Retreat. Digital Applications for Smart Health. Los Angeles 2017
- Conference Speaker, American Cancer Society Cancer Action Network Forum, Challenges in Clinical Trials, Los Angeles, 2017
- Invited Speaker, Los Angeles Otolaryngology Society, Immunotherapy for Head and Neck Cancer, Los Angeles 2018
- Invited Speaker, American Association of Cancer Research Annual Meeting, Opening Plenary Session, Physicist vs Physician, Atlanta, GA 2019

- Invited Speaker, Foundation for the National Institutes of Health Biomarkers Consortium, Cachexia Working Group Workshop, Toward Objective Measures of Performance Status, Bethesda, MD 2019
- Invited Speaker, Los Angeles Radiologic Society Annual Conference, Immunotherapy of Lung Cancer, Long Beach, CA 2019
- Plenary Speaker, American Association of Cancer Research Annual Meeting, Digitizing the Patient, Atlanta 2019
- Invited Speaker, Cachexia Deep Dive Meeting, FNIH, Objective Metrics of Human Performance, North Bethesda, Maryland, 2019
- Invited Speaker, International Society for Biological and Environmental Repositories, Digital Tools that Complement Biobanks, Minneapolis, MN 2019
- Invited Speaker, Digital Innovation to Improve Oncology Clinical Trials and Remote Patient Care in Clinical Trial Partnerships in Oncology virtual conference, 2021
- Invited Speaker, Rethinking Innovation in Cancer Research and Care" -Karnofsky revisited – digital tools to make performance status an objective measure in oncology. Virtual conference 2021
- Invited Speaker, Outcome Measures for Cancer Cachexia, Cancer Cachexia Society Annual Meeting (Clinical Advances in Cancer Cachexia), virtual conference 2021

Invited Grand Rounds/CME Lectures Invited

- Grand Rounds, Circulating Tumor Cells in Predicting Cancer Outcomes, Billings Clinic, Billings, MT, 2008
- Grand Rounds, Personalized Therapy for Lung Cancer, Billings Clinic, Billings, MT, 2009
- Grand Rounds, Lung Cancer Screening, Billings Clinic, Billings MT, 2011
- Grand Rounds, Breast Cancer Update, Livingston Memorial Hospital, Livingston MT, 2011
- Grand Rounds, Novel Immunotherapies for Cancer, Billings Clinic, Billings, MT, 2012
- Grand Rounds, Systemic Therapy for NSCLC, Verdugo Hills Hospital, Glendale, CA, 2014
- CME Lecture, Immunotherapy: USC's Multi-Disciplinary Thoracic Oncology Conference, Pasadena, 2015
- CME Lecture, Fluid Biopsy: USC's MultiD Thoracic Oncology Conference, Pasadena, CA, 2016
- CME Lecture, Genomic Testing for Lung Cancer, Who, What, Where, When and How: USC's MultiD Thoracic Oncology Conference, Pasadena, CA 2017
- CME Lecture, Immunotherapy for Metastatic Lung Cancer, Global Lung Health Summit, Tuscon, AZ 2018
- Grand Rounds Lecture, Immunotherapy for Metastatic Lung Cancer, Eisenhower Medical Center, Palm Desert, CA 2018
- CME Lecture, Update on Genomic Testing in Lung Cancer, USC Multidisciplinary Lung Cancer Conference, Marina Del Rey, CA 2019

Grand Rounds, Immunotherapy in Non Small Cell Lung Cancer, Huntington Hospital,
Pasadena, CA 2019

Grand Rounds, Immunotherapy in Metastatic Lung Cancer, Providence Holy Cross
Hospital, Mission Hills, CA 2019

F. Research Activities:

Cancer Diagnostic and Prognostic Technologies

Mathematical Modeling of Cancer Progression

Clinical Trials in Lung Cancer and Head/Neck Cancer

Digital Tools for Objective Measurement of Performance Status

G. Research Grants:

Active

1. USC Norris Comprehensive Cancer Center (Core) Grant, P30 CA014089, NIH/NCI, Lerman (PI), Nieva (Chair, DSMC), 12/01/96-11/30/20
2. Ming Hseih Foundation, Establishing a Diagnosis of Lung Cancer through a Fluid Biopsy (PI-Kuhn) 2019-2020
3. A phase II study of subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model.

Completed

1. A Phase IIa Trial of sEphB4-HSA in Combination with Pembrolizumab in Patients with Non-Small Cell Lung and Head/Neck Cancer, #53085 IISP, Merck, Nieva (PI), 04/25/17-04/25/18
2. Four-Dimensional Heterogeneity of Fluid Phase Biopsies in Cancer (4DB Center), U54 CA143906, NIH/NCI, Kuhn (PI), Nieva (Co-Investigator), 09/30/09-08/31/15
3. A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer, #NCIC CTG BR.31, Clinipace, Inc., Nieva (PI), 08/04/15-12/31/20
4. A Phase 1b Multi-Arm Study of sEphB4-HSA in Combination with Different Chemotherapy Regimens in Patients with Advanced Solid Tumors, Whittier Foundation, El-Khoueiry (PI), Nieva (Co-Investigator) 04/01/15-03/31/16
5. Analytic Tools for the Objective Monitoring of Human Performance (ATOM-HP), FFP-012016-0001 (USA051), Noetic Corporation (NIH), Williams (PI), Nieva (PI, Subcontract), 09/30/15-09/29/17
6. Circulating Tumor Cells in Non-Small Cell Lung Cancer, R01 CA125653, NIH/NCI, Nieva (PI), 09/24/07-07/31/12
7. High Speed Reliable Detection of Cancer Cells in Blood, R01 CA111359, NIH/NCI, Bruce (PI), Nieva (Co-Investigator), 09/06/06-07/31/11
8. Investigating the Link between the Atheronals and Aging, R21 AG028300, NIH/NIA, Wentworth (PI), Nieva (Co-Investigator), 08/15/06-06/30/08
9. Pharmacokinetic Effects of Aprepitant on Irinotecan, #26488 IISP, Merck, Nieva (PI), 2005-2007

H. Bibliography:

Peer Reviewed

1. Stuart MJ, Smith AM, **Nieva JJ**, Rock MG. Injuries in youth ice hockey: a pilot surveillance strategy. *Mayo Clin Proc* 70:350-356, 1995.

2. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, **Nieva J**, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babior BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. *Science* 298:2195-2199, 2002.
3. **Nieva J**, Del Zoppo G. Understanding coagulopathies. *Emerg Med* 35:35-44, 2003.
4. **Nieva J**, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. *Blood* 102:810-813, 2003.
5. Wentworth P Jr, **Nieva J**, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. *Science* 302:1053-1056, 2003.
6. **Nieva J**, Saven A. Cladribine activity in systemic mast cell disease: application of biochemistry in the modern era of molecular biology. *Leuk Res* 28:113-114, 2004.
7. Zhang Q, Powers ET, **Nieva J**, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P Jr, Lerner RA, Kelly JW. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. *Proc Natl Acad Sci USA* 101:4752-4757, 2004.
8. **Nieva J**, Wentworth P Jr. The antibody-catalyzed water oxidation pathway--a new chemical arm to immune defense? *Trends Biochem Sci* 29:274-278, 2004.
9. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, Senent ML, **Nieva J**, Sanz GF, Sanz MA, Saven A, Mustelin T. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. *Br J Haematol* 129:791-794, 2005.
10. **Nieva J**, Kerwin L, Wentworth AD, Lerner RA, Wentworth P Jr. Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. *Immunol Lett* 103:33-38, 2006.
11. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, **Nieva J**. High speed detection of circulating tumor cells. *Biosens Bioelectron* 21:1893-1899, 2006.
12. Bosco DA, Fowler DM, Zhang Q, **Nieva J**, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. *Nat Chem Biol* 2:249-253, 2006.

13. Takeuchi C, Galve R, **Nieva J**, Witter DP, Wentworth AD, Troseth RP, Lerner RA, Wentworth P Jr. Proatherogenic effects of the cholesterol ozonolysis products, atheronal-A and atheronal-B. *Biochemistry* 45:7162-7170, 2006.
14. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, **Nieva J**, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. *N Engl J Med* 355:1672-1681, 2006.
15. Nerenberg M, Kariv I, McNeeley P, Marchand P, Sur S, Diver J, Riccitelli S, **Nieva J**, Saven A. Use of optophoresis as an *in vitro* predictor of cell response to chemotherapy for chronic lymphocytic leukemia. *Leuk Lymphoma* 47:2194-2202, 2006.
16. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, **Nieva J**, Kuhn P. Case study of the morphologic variation of circulating tumor cells. *Hum Pathol* 38:514-519, 2007.
17. **Nieva J**. The clinical significance of circulating tissue factor in prostate cancer. *Thromb Haemost* 97:329-330, 2007.
18. **Nieva J**, Saven A. Understanding hairy cell leukemia genetics. *Leuk Lymphoma* 48:653-654, 2007.
19. Tilley RE, Holscher T, Belani R, **Nieva J**, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. *Thromb Res* 122:604-609, 2008. PMID: PMC2572216
20. **Nieva J**. Genetics of hairy cell leukemia. *Oncol Rev* 1:189-194, 2008. PMID: N/A
21. **Nieva J**, Shafton A, Altobelli LJ 3rd, Tripuraneni S, Rogel JK, Wentworth AD, Lerner RA, Wentworth P Jr. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation. *Biochemistry* 47:7695-7705, 2008. PMID: N/A
22. Martin FM, Prchal J, **Nieva J**, Saven A, Andrey J, Bethel K, Barton JC, Aripally G, Bottomley SS, Friedman JS. Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. *Br J Haematol* 143:446-450, 2008. PMID: PMC2603068
23. Wentworth AD, Song BD, **Nieva J**, Shafton A, Tripuraneni S, Wentworth P Jr. The ratio of cholesterol 5,6-secosterols formed from ozone and singlet oxygen offers insight

- into the oxidation of cholesterol *in vivo*. *Chem Commun (Camb)* 3098-3100, 2009. PMID: PMC2819220
24. Marrinucci D, Bethel K, Luttgen M, Bruce RH, **Nieva J**, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. *Arch Pathol Lab Med* 133:1468-1471, 2009. PMID: PMC4422331
 25. Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, Bruce R, **Nieva J**, Kuhn P. Cytomorphology of circulating colorectal tumor cells: a small case series. *J Oncol* 2010:861341, 2010. PMID: PMC2810476
 26. **Nieva J**, Song BD, Rogel JK, Kujawara D, Altobel L, 3rd, Izharrudin A, Boldt GE, Grover RK, Wentworth AD, Wentworth P Jr. Cholesterol secosterol aldehydes induce amyloidogenesis and dysfunction of wild-type tumor protein p53. *Chem Biol* 18:920-927, 2011. PMID: PMC3148486
 27. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, **Nieva J**, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature* 477:99-102, 2011. PMID: N/A
 28. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, **Nieva J**, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. *Phys Biol* 9:016001, 2012. PMID: PMC3387999
 29. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, **Nieva J**, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. *Phys Biol* 9:016003, 2012. PMID: PMC3387996
 30. **Nieva J**, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. *Phys Biol* 9:016004, 2012. PMID: PMC3388002
 31. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, **Nieva J**, Heuvel M, Kuhn P.

- Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. *Phys Biol* 9:016005, 2012. PMID: PMC3387995
32. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, **Nieva JJ**, Wakelee HA, Bruce RH. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. *Lung Cancer* 77:421-426, 2012. PMID: N/A
 33. Newton PK, Mason J, Bethel K, Bazhenova LA, **Nieva J**, Kuhn P. A stochastic Markov chain model to describe lung cancer growth and metastasis. *PLoS One* 7:e34637, 2012. PMID: PMC3338733
 34. Jatoi A, **Nieva JJ**, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC. A pilot study of long-acting octreotide for symptomatic malignant ascites. *Oncology* 82:315-320, 2012. PMID: PMC3559024
 35. **Nieva JJ**, Kuhn P. Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. *Future Oncol* 8:989-998, 2012. PMID: PMC3658625
 36. Newton PK, Mason J, Bethel K, Bazhenova L, **Nieva J**, Norton L, Kuhn P. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. *Cancer Res* 73:2760-2769, 2013. PMID: PMC3644026
 37. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, **Nieva J**, Gambhir SS, Kuhn P. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. *PLoS One* 8:e67733, 2013. PMID: PMC3702496
 38. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, **Nieva J**, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. *Cancer* 119:2383-2390, 2013. PMID: PMC3686910
 39. Bazhenova L, Newton P, Mason J, Bethel K, **Nieva J**, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. *J Thorac Oncol* 9:442-446, 2014. PMID: PMC3989547

40. Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanaawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW Jr, Shrager JB, Bethel K, Hoh CK, Bazhenova L, **Nieva J**, Kuhn P, Gambhir SS. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. *J Thorac Oncol* 9:1111-1119, 2014. PMID: PMC4145608
41. Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, **Nieva J**, Kuhn P. Entropy, complexity, and Markov diagrams for random walk cancer models. *Sci Rep* 4:7558, 2014. PMID: PMC4894412
42. Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, **Nieva J**, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. *Oral Oncol* 51:376-382, 2015. PMID: PMC4459134
43. Burke J, **Nieva J**, Borad MJ, Breitbach CJ. Oncolytic viruses: perspectives on clinical development. *Curr Opin Virol* 13:55-60, 2015. PMID: N/A
44. **Nieva J**, Bethel K, Baas, C, Kuhn P. Convergent science physical oncology. *Converg Sci Phys Oncol* 1:010201, 2015.
45. In GK, **Nieva J**. Emerging chemotherapy agents in lung cancer: nanoparticle therapeutics for non-small cell lung cancer. *Transl Cancer Res* 4:340-355, 2015.
46. Newton PK, Mason J, Venkatappa N, Jochelson MS, Hurt B, **Nieva J**, Comen E, Norton L, Kuhn P. Spatiotemporal progression of metastatic breast cancer: A Markov chain model highlighting the role of early metastatic sites. *NPJ Breast Cancer* 1:15018, 2015. PMID: PMC5515198
47. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, **Nieva J**, Zhao X, Schell M, Sullivan DM. A randomized Phase II study of Linsitinib (OSI-906) versus Topotecan in patients with relapsed small-cell lung cancer. *Oncologist* 21:1163-1164, 2016. PMID: PMC5061534
48. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magana M, Makani S, Bazhenova L, Dittamore RV, **Nieva J**. Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival. *Cancer Epidemiol Biomarkers Prev* 26:1139-1145, 2017. PMID: PMC5500408

49. In GK, Mason J, Lin S, Newton PK, Kuhn P, **Nieva J**. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. *Converg Sci Phys Oncol* 3:035002, 2017. PMC Journal – In Process
50. Su DW, **Nieva J**. Biophysical technologies for understanding circulating tumor cell biology and metastasis. *Transl Lung Cancer Res* 6:473-485, 2017. PMID: PMC5583073
51. Rodríguez-Lee M, Kolatkar A, McCormick M, Dago AD, Kendall J, Carlsson NA, Bethel K, Greenspan EJ, Hwang SE, Waitman KR, **Nieva JJ**, Hicks J, Kuhn P Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. *Arch Pathol Lab Med*. 2018 Feb;142(2):198-207. doi: 10.5858/arpa.2016-0483-OA. Epub 2017 Nov 16. PMID: 29144792
52. **Nieva J**, Hicks J. When it comes to genomic analysis of tumours, don't buy in bulk. *Br J Cancer*. 2018 May 10. doi: 10.1038/s41416-018-0096-8. [Epub ahead of print] PMID: 29743553
53. Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, **Nieva J**, Kuhn P, Newton PK. Low-dimensional dynamical characterization of human performance of cancer patients using motion data. *Clin Biomech (Bristol,Avon)*. 2018 Jul;56:61-69 PMID 29803824
54. Yang SC, Welter L, Kolatkar A, **Nieva J**, Waitman KR, Huang KF, Liao WH, Takano S, Berelson WM, West AJ, Kuhn P, John SG. A new anion exchange purification method for Cu stable isotopes in blood samples. *Anal Bioanal Chem*. 2019 Jan;411(3):765-776. doi: 10.1007/s00216-018-1498-4. Epub 2018 Nov 22. PMID: 30467768
55. Hassani C, Varghese BA, **Nieva J**, Duddalwar V. Radiomics in Pulmonary Lesion Imaging. *AJR Am J Roentgenol*. 2019 Mar;212(3):497-504. doi: 10.2214/AJR.18.20623. Epub 2019 Jan 8. PMID: 30620678
56. Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, **Nieva JJ**, Cheever MA, Nghiem PT, Sharon E. Tuberculosis following PD-1 blockade for cancer immunotherapy. *Sci Transl Med*. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702. PMID: 30651320
57. Jarrell JA, Twite AA, Lau KHWJ, Kashani MN, Lievano AA, Acevedo J, Priest C, **Nieva J**, Gottlieb D, Pawell RS Intracellular delivery of mRNA to human primary T

- cells with microfluidic vortex shedding. *Sci Rep.* 2019 Mar 1;9(1):3214. doi: 10.1038/s41598-019-40147-y. PMID: 30824814
58. Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, **Nieva JJ**, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV. Detection of NRG1 Gene Fusions in Solid Tumors. *Clin Cancer Res.* 2019 Apr 15. doi: 10.1158/1078-0432.CCR-19-0160 PMID: 30988082
59. Ye JC, Ding L, Atay SM, **Nieva JJ**, McFadden PM, Chang E, Kim AW. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer. *Semin Thorac Cardiovasc Surg.* 2019 Jun 17. pii: S1043-0679(19)30172-8. doi: 10.1053/j.semtcvs.2019.06.002. [Epub ahead of print] PMID: 31220530
60. Broderick J, May M, Schwartz JE, Li M, Mejia A, Nocera L, Kolatkar A, Ueno NT, Yennu S, Lee J, Hanlon S, Cozzens-Philips FA, Shahabi C, Kuhn P, **Nieva J**. Patient Reported Outcomes Can Improve Performance Status Assessment: A Pilot Study. *J Patient Rep Outcomes.* 2019 Jul 16;3(1):41. PMID: 31313047
61. Shishido SN, Carlsson A, **Nieva J**, Bethel K, Hicks JB, Bazhenova L, Kuhn P. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. *J Transl Med.* 2019 Aug 28;17(1):294. PMID: 31462312
62. Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, **Nieva JJ**, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study. *J Thorac Oncol.* 2019 Oct 9. pii: S1556-0864(19)33411-2. PMID: 31605793
63. Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials. Cheng JH, Tiulim JW, Zhou S, El-Khoueiry A, **Nieva J**. *Front Oncol* 2019 Oct 18;9:968 PMID31681560
64. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, **Nieva J**, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. *J Thorac Oncol.* 2019 Nov;14(11):1901-1911. PMID: 31446141
65. Shishido SN, Welter L, Rodriguez-Lee M, Kolatkar A, Xu L, Ruiz C, Gerdtsen AS, Restrepo-Vassalli S, Carlsson A, Larsen J, Greenspan EJ, Hwang ES, Waitman KR, **Nieva J**, Bethel K, Hicks J, Kuhn P. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of

- Breast Cancer Patients. *J Mol Diagn.* 2020 Mar;22(3):319-337. doi: 10.1016/j.jmoldx.2019.11.006. Epub 2020 Jan 22. PMID: 31978562
66. Gerdtsen AS, Thiele JA, Shishido SN, Zheng S, Schaffer R, Bethel K, Curley S, Lenz HJ, Hanna DL, **Nieva J**, Kolatkar A, Ruiz C, Rodriguez-Lee M, Oakley Iii GJ, Lee JSH, Hicks J, Kuhn P. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. *Oncotarget.* 2019 Dec 17;10(66):7016-7030. doi: 10.18632/oncotarget.27271. eCollection 2019 Dec 17. PMID: 31903162
67. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchsacher GL Jr, Garrido P, **Nieva J**, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: *Lancet Oncol.* 2020 Feb;21(2):e70. PMID: 31838007
68. Coyne GO, Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, **Nieva JJ**, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarczyk RL, Kummar S, Chen AP, Doroshow JH. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. PMID: 32314030
69. Tanachat Nilanon, Luciano P Nocera, Alexander S Martin, Anand Kolatkar, Marcella May, Zaki Hasnain, Naoto T Ueno, Sriram Yennu, Angela Alexander, Aaron E Mejia, Roger Wilson Boles, Ming Li, Jerry S H Lee, Sean E Hanlon, Frankie A Cozzens Philips, David I Quinn, Paul K Newton, Joan Broderick, Cyrus Shahabi, Peter Kuhn, **Jorge J Nieva**. Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. *JCO Clin Cancer Inform.* 2020 Sep;4:839-853. doi: 10.1200/CCI.29.0023. PMID: 32970482
70. Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi, Benjamin Besse, Sant P Chawla, Lyudmila Bazhenova, John C Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido-Laguna, Stephen V Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H Loong, Gary L Buchsacher Jr, Pilar Garrido, **Jorge Nieva**, Conor Steuer, Tobias R Overbeck, Daniel W Bowles, Elizabeth Fox, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, George D

- Demetri, trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020 Feb;21 (2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. PMID: 31838007
71. Zaki Hasnain, Tanachat Nilanon, Ming Li, Aaron Mejia, Anand Kolatkar, Luciano Nocera, Cyrus Shahabi, Frankie A Cozzens Philips, Jerry S H Lee, Sean E Hanlon, Poorva Vaidya, Naoto T Ueno, Sriram Yennu, Paul K Newton, Peter Kuhn, **Jorge Nieva**. Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. *JCO Clin Cancer Inform.* 2020 Jun;4:583-601. doi: 10.1200/CCI.20.00010. PMID: 32598197
72. Elizabeth Pan, David Bogumil, Victoria Cortessis, Sherrie Yu, **Jorge Nieva**. A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs. *Front Oncol.* 2020 Apr 23;10:591. doi: 10.3389/fonc.2020.00591. eCollection 2020. PMID: 32391273
73. Nilanon T, Nocera LP, **Nieva JJ**, Shahabi C. Towards Automated Performance Status Assessment: Temporal Alignment of Motion Skeleton Time Series. In *Explainable AI in Healthcare and Medicine, Studies in Computational Intelligence.* p335-344. Springer 2020
74. Green HE, **Nieva J** Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer *Journal of Investigative Medicine*, Published Online First: 14 June 2021. doi: 10.1136/jim-2021-001806
75. Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, **Nieva JJ**, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. *J Thorac Oncol.* 2020 Jan;15(1):110-119. doi: 10.1016/j.jtho.2019.09.083. Epub 2019 Oct 9.
76. Welter L, Xu L, McKinley D, Dago AE, Prabakar RK, Restrepo-Vassalli S, Xu K, Rodriguez-Lee M, Kolatkar A, Nevarez R, Ruiz C, **Nieva J**, Kuhn P, Hicks Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. *J Cold Spring Harb Mol Case Stud.* 2020 Dec 17;6(6):a005819. doi: 10.1101/mcs.a005819. Print 2020 Dec. PMID: 33203646

77. Jonna S, Vanderwalde A, Nieva J, Poorman KA, Saul M, von Buttlar X, Hu JY, Liu SV Effect of prior therapy on tumor mutational burden in NSCLC. *Transl Lung Cancer Res.* 2021 Mar;10(3):1231-1238. doi: 10.21037/tlcr-20-1076.PMID: 33889505
78. Ris F, Hellan M, Douissard J, Nieva JJ, Triponez F, Woo Y, Geller D, Buchs NC, Buehler L, Moenig S, Iselin CE, Karenovics W, Petignat P, Lam GT, Undurraga Malinervo M, Tuttle R, Ouellette J, Bose D, Ismail N, Toso C. Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results. *Cancers (Basel).* 2021 Aug 15;13(16):4104. doi: 10.3390/cancers13164104.PMID: 34439258
79. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). *Lung Cancer.* 2021 Oct;160:92-98. doi: 10.1016/j.lungcan.2021.08.010. Epub 2021 Aug 27.PMID: 34482103
80. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. *Mol Cancer Ther.* 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13.PMID: 34518295
81. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. *Oncotarget.* 2021 Dec 7;12(25):2449-2458. doi: 10.18632/oncotarget.28132. eCollection 2021 Dec 7.PMID: 34917263
82. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. *Br J Cancer.* 2022 Feb;126(3):514-520. doi: 10.1038/s41416-021-01536-1. Epub 2021 Sep 3.PMID: 34480094